Carrigan G, Bradbury BD, Brookhart MA, Capra WB, Chia V, Rothman KJ, Sarsour K, Taylor MD, Brown JS. External comparator groups derived from real-world data used in support of regulatory decision making: use cases and challenges. Curr Epidemiol Rep. 2022 Dec;9:326-37. doi: 10.1007/s40471-022-00305-9
Mahmoudi E, Lin P, Ratakonda S, Khan A, Kamdar N, Peterson MD. Preventative services use and risk reduction for potentially preventative hospitalizations among people with traumatic spinal cord injury. Arch Phys Med Rehabil. 2022 Jul;103(7):1255-62. doi: 10.1016/j.apmr.2021.12.004
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Margulis AV, Anthony M, Rivero-Ferrer E. Drug safety in pregnancy: review of study approaches requested by regulatory agencies. Curr Epidemiol Rep. 2019 Sep;6(3):380-9. doi: 10.1007/s40471-019-00212-6
Kamptner NL, Teyber FH, Rockwood NJ, Drzewiecki D. Evaluating the efficacy of an attachment-informed psychotherapeutic program for incarcerated parents. J Prison Educ Reentr. 2017 Dec;4(2):62-81.
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
White MV, Hogue SL, Odom D, Cooney D, Bartsch J, Goss D, Hollis K, Herrem C, Silvia S. Anaphylaxis in schools: results of the EPIPEN4SCHOOLS survey combined analysis. Pediatr Allergy Immunol Pulmonol. 2016 Sep;29(3):149-54. doi: 10.1089/ped.2016.0675
White MV, Goss D, Hollis K, Millar K, Silvia S, Siegel PH, Bennett ME, Wooddell MJ, Hogue SL. Anaphylaxis triggers and treatments by grade level and staff training: findings from the EPIPEN4SCHOOLS pilot survey. Pediatr Allergy Immunol Pulmonol. 2016 Jun 16;29(2):80-5. doi: 10.1089/ped.2015.0614
Mansfield C, Viswanathan M, Woodell C, Ohadike YU, Kennedy Lesch LJ, Malveaux FJ. Improving asthma outcomes for children: many paths to progress. Pediatr Allergy Immunol Pulmonol. 2015 Jun;28(2):80-6. doi: 10.1089/ped.2014.0440
Andrews EB, Margulis AV, Tennis PS, West SL. Opportunities and challenges in using epidemiologic methods to monitor drug safety in the era of large automated health databases. Curr Epidemiol Rep. 2014 Oct 12;1(4):194-205.
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Arellano FM, Arana A, Wentworth CE, Vidaurre CF, Chipps BE. Prescription patterns for asthma medications in children and adolescents with health care insurance in the United States. Pediatr Allergy Immunol Pulmonol. 2011;22(5):469-76.
Brodtkorb T, Henriksson M, Johannesen-Munk K, Thidell F. Cost-effectiveness of C-leg compared with non-microprocessor-controlled knees: a modeling approach. Arch Phys Med Rehabil. 2008;89(1):24-30.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.